Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlitelimab in moderate to severe hidradenitis suppurativa
NCT06118099Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Nov 2023
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of amlitelimab in hidradenitis suppurativa (HS), sponsored by Sanofi. Started Nov 2023; status: terminated.
02
Drugs
amlitelimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06118099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06118099.